Use of Memantine (akatinol) for the Correction of Cognitive Impairments in Parkinson’s Disease Complicated by Dementia
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
This study addresses the effects of 52 weeks of treatment with the NMDA glutamate receptor antagonist memantine on motor, cognitive, and mental disorders in patients with Parkinson’s disease complicated by dementia, as compared with a control group of patients not treated with memantine. Patients of the experimental group (32 subjects) received memantine (20 mg/day), while patients in the control group continued on antiparkinsonism treatment alone. Cognitive, psychiatric, and motor symptoms were assessed before the study and then at the ends of weeks 12, 24, and 52, using clinical assessment, rating scales, and neuropsychological tests. Plasma homocysteine levels were measured by HPLC. Patients treated with memantine had better measures on the MMSE (p < 0.05), ADAS-cog (p < 0.05), clock drawing test (p < 0.05), and FAB (p < 0.01) as compared with the control group by the end of study week 24. Members of the group of patients with high homocysteine levels mounted significantly better responses with memantine treatment, as compared with patients of the control group with high homocysteine levels but not receiving memantine, at the ends of study weeks 24 and 52, in terms of all rating scales (UPDRS, MMSE, ADAS-cog, D-KEFS Verbal Fluency Test, FAB. NPI, and DAD, p < 0.05). By the end of week 52, significant changes in points scores on the NPI-12 scale from baseline were in favor of patients receiving memantine, this applying to the disinhibition (p = 0.006), irritability (p = 0.04), anxiety (p = 0.04), and hallucinations (p = 0.048) subscales. The presence of hyperhomocysteinemia may indicate faster progression of both motor and cognitive impairments in Parkinson’s disease. Prolonged memantine treatment of patients with Parkinson’s disease complicated by dementia leads to improvements in cognitive functions, stabilization of motor impairments, and decreases in the severity of mental disorders, especially in patients with hyperhomocysteinemia.
- D. V. Artem’ev and Zh. M. Glozman, “Impairments to higher mental functions in Parkinson’s disease,” in : Advances in Neurodegeneration [in Russian], Moscow (1995), pp. 46–60.
- S. I. Gavrilova, Ya. B. Kalyn, I. V. Kolykhalov, et al., “Akatinol memantine – a modulator of the glutamatergic system in the treatment of Alzheimer’s-type dementia,” Sots. Klin. Psikhiat., 5, No. 2, 78–89 (1995).
- O. S. Levin, “Efficacy of reminil in Lewy body dementia,” Zh. Nevropatol. Psikhiat., 105, No. 10, 15–21 (2005).
- I. V. Litvinenko and M. M. Odinak, “Pathogenetic bases of the formation of cognitive and psychotic impairments in Parkinson’s disease,” Zh. Nevrol. Psikhiat., 4, 76–81 (2004).
- I. V. Litvinenko, Parkinson’s Disease [in Russian], Miklosh, Moscow (2006), p. 216.
- M. N. Puzin, O. V. Krivonos, and Zh. V. Kozhevnikova, “Akatinol memantine in the treatment of cognitive impairments in Parkinson’s disease,” Zh. Nevrol. Psikhiat., 107, No. 1, 26–29 (2007).
- N. N. Yakhno, T. V. Akhutina, and V. V. Zakharov, “Memory impairments in Parkinson’s disease,” in: Proc. of the 7th All-Russian Congr. of Neurologists [in Russian], N. Novgorod (1995), p. 573.
- D. Aarsland, K. Andresen, J. P. Larsen, et al., “Risk of dementia in Parkinson’s Disease: A community-based prospective study,” Neurology, 56, No. 6, 730–736 (2001).
- D. Aarsland, M. Hutchinson, and J. P. Larsen, “Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia,” Int. J. Geriat. Psychiat., 18, No. 10, 937–941 (2003). CrossRef
- D. Aarsland, K. Brønnick, U. Ehrt, et al., “Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress,” J. Neurol. Neurosurg. Psychiatr., 78, 36–42 (2007). CrossRef
- G. E. Alexander, M. R. DeLong, and P. L. Strick, “Parallel organization of functionally segregated circuits linking basal ganglia and cortex,” Ann. Rev. Neurosci., 9, 357–381 (1986). CrossRef
- I. Blasko, K. Jellinger, G. Kemmler, et al., “Conversion from cognitive health to mild cognitive impairment and Alzheimer’s disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine,” Neurobiol. Aging, 29, No. 1, 1–11 (2008). CrossRef
- J. L. Boyd, C. A. Cruickshank, C. W. Kenn, et al., “Cognitive impairment and dementia in Parkinson’s disease: a controlled study,” Psychological. Med., 21, No. 3, 911–921 (1991). CrossRef
- T. C. Buter, A. Van den Hout, F. E. Matthews, et al., “Dementia and survival in Parkinson disease: a 12-year population study,” Neurology, 70, No. 13, 1017–1022 (2008). CrossRef
- A. S. Caumont, J. N. Octave, and E. Hermans, “Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells,” Neurosci. Lett., 394, No. 3, 196–201 (2006). CrossRef
- J. L. Cummings, M. Mega, K. Gray, et al., “The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia,” Neurology, 44, No. 12, 2308–2314 (1994).
- N. Egashira, R. Okuno, S. Harada, et al., “Effects of glutamate-related drugs on marble-burying behavior in mice: Implications for obsessive-compulsive disorder,” Eur. J. Pharmacol. (E-publication ahead of print) (2008).
- M. Emre, “Dementia associated with Parkinson’s disease,” Lancet Neurol., 2, No. 4, 229–237 (2003). CrossRef
- M. Emre, D. Aarsland, A. Albanese, et al., “Rivastigmine for dementia associated with Parkinson’s disease,” New Eng. J. Med., 351, 2509–2518 (2004). CrossRef
- G. Fabbrini, P. Barbanti, C. Aurilia, et al., “Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease,” Neurol. Sci., 23, No. 1, 41–43 (2002). CrossRef
- M. Giustizieri, M. L. Cucchiaroni, R. Guatteo, et al., “Memantine inhibits ATP-dependent K+ conductances in dopamine neurons of the rat substantia nigra pars compacta,” J. Pharmacol. Exp. Ther., 322, No. 2, 721–729 (2007). CrossRef
- R. Inzelberg, U. Bonuccelli, E. Schechtman, et al., “Association between amantadine and the onset of dementia in Parkinson’s disease,” Mov. Dis., 21, No. 9, 1375–1379 (2006). CrossRef
- Y. Luo, X. Zhou, X. Yang, and J. Wang, “Homocysteine induces tau hyperphosphorylation in rats,” Neuroreport, 18, No. 18, 2005–2008 (2007). CrossRef
- J. Martinez-Martin, A. Cil-Nagel, L. Morlan-Garcia, et al., “Unified Parkinson’s Disease Rating Scale: characteristics and structure,” Mov. Dis., 9, 76–83 (1994). CrossRef
- M. Merello, M. I. Nouzeilles, A. Cammarota, and R. Leiguarda, “Effect of memantine (NMDA antagonist) on Parkinson’s disease: a double-blind crossover randomized study,” Clin. Neuropharmacol., 22, No. 5, 273–276 (1999).
- C. G. Parsons, W. Danysz, and G. Quack, “Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist – a review of preclinical data,” Neuropharmacology, 38, No. 3, 735–767 (1999). CrossRef
- M. Pasquini and M. Biondi, “Memantine augmentation for refractory obsessive-compulsive disorder,” Prog. Neuropsychopharmacol. Biol. Psychiat., 30, No. 6, 1173–1175 (2006). CrossRef
- M. Poyurovsky, R. Weizman, A. Weizman, and L. Koran, “Memantine for treatment-resistant OCD,” Am. J. Psychiat., 162, No. 11, 2191–2192 (2005). CrossRef
- D. Religa, K. Czyzewski, M. Styczynska, et al., “Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson’s disease,” Neurosci. Lett., 404, No. 1–2, 56–60 (2006). CrossRef
- M. Rosler, “The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia,” Int. J. Clin. Pract., 127, Supplement 1, 20–26 (2002).
- P. Seeman, C. Caruso, M. Lasaga, “Memantine agonist action at dopamine D2High receptors,” Synapse, 62, No. 2, 149–153 (2008). CrossRef
- C. B. Wright, H. S. Lee, M. C. Paik, et al., “Total homocysteine and cognition in a tri-ethnic cohort: the Northern Manhattan Study,” Neurology, 63, No. 2, 254–260 (2004).
- Use of Memantine (akatinol) for the Correction of Cognitive Impairments in Parkinson’s Disease Complicated by Dementia
Neuroscience and Behavioral Physiology
Volume 40, Issue 2 , pp 149-155
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Parkinson’s disease